WO2001083527A3 - Glucagon antagonists - Google Patents

Glucagon antagonists Download PDF

Info

Publication number
WO2001083527A3
WO2001083527A3 PCT/US2001/014321 US0114321W WO0183527A3 WO 2001083527 A3 WO2001083527 A3 WO 2001083527A3 US 0114321 W US0114321 W US 0114321W WO 0183527 A3 WO0183527 A3 WO 0183527A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
vehicle
glucagon antagonist
preferred
glucagon
Prior art date
Application number
PCT/US2001/014321
Other languages
French (fr)
Other versions
WO2001083527A2 (en
Inventor
William S Marshall
Kevin Lee Stark
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to EP01929003A priority Critical patent/EP1278772A2/en
Priority to JP2001580951A priority patent/JP2003531632A/en
Priority to AU2001255798A priority patent/AU2001255798A1/en
Publication of WO2001083527A2 publication Critical patent/WO2001083527A2/en
Publication of WO2001083527A3 publication Critical patent/WO2001083527A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
PCT/US2001/014321 2000-05-03 2001-05-03 Glucagon antagonists WO2001083527A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01929003A EP1278772A2 (en) 2000-05-03 2001-05-03 Glucagon antagonists
JP2001580951A JP2003531632A (en) 2000-05-03 2001-05-03 Glucagon antagonist
AU2001255798A AU2001255798A1 (en) 2000-05-03 2001-05-03 Glucagon antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20143600P 2000-05-03 2000-05-03
US60/201,436 2000-05-03
US09/847,249 2001-05-02
US09/847,249 US6677136B2 (en) 2000-05-03 2001-05-02 Glucagon antagonists

Publications (2)

Publication Number Publication Date
WO2001083527A2 WO2001083527A2 (en) 2001-11-08
WO2001083527A3 true WO2001083527A3 (en) 2002-08-01

Family

ID=26896746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014321 WO2001083527A2 (en) 2000-05-03 2001-05-03 Glucagon antagonists

Country Status (5)

Country Link
US (1) US6677136B2 (en)
EP (1) EP1278772A2 (en)
JP (1) JP2003531632A (en)
AU (1) AU2001255798A1 (en)
WO (1) WO2001083527A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7562012B1 (en) * 2000-11-03 2009-07-14 Audible Magic Corporation Method and apparatus for creating a unique audio signature
EP2581383A1 (en) * 2002-11-25 2013-04-17 Genencor International, Inc. Skin or hair binding peptides
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
ATE555133T1 (en) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd IGG FC FRAGMENT FOR A MEDICINAL CARRIER AND METHOD FOR THE PRODUCTION THEREOF
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
US20190330295A1 (en) * 2005-05-04 2019-10-31 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
ES2572952T3 (en) * 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Glucagon analogs showing physiological solubility and stability
CN101389648B (en) 2006-02-22 2013-07-17 默沙东公司 Oxyntomodulin derivatives
CN101578102B (en) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
EP2487184A1 (en) * 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2009058662A2 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
AU2008318876B2 (en) * 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
JP2011511778A (en) * 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Ester-based peptide prodrugs
EP2952202B1 (en) * 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
TWI474832B (en) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CA2727161A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
MX2012008603A (en) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
BR112012028707A2 (en) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp glucagon compound of the peptide superfamily exhibiting g receptor activity with coupled protein, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
RU2739209C2 (en) 2011-06-10 2020-12-21 Ханми Сайенс Ко., Лтд. Novel oxyntomodulin derivatives and a pharmaceutical composition containing them for treating obesity
TR201901402T4 (en) 2011-06-17 2019-02-21 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment and its use.
WO2012177444A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US9944687B2 (en) * 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
CN103958682A (en) * 2011-10-21 2014-07-30 诺松制药股份公司 Glucagon binding nucleic acids
KR20140097151A (en) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
AR091477A1 (en) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEIVER ACTIVITY
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
CN108271356A (en) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 Duodenin-insulin conjugate
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
EA035527B1 (en) 2014-12-30 2020-06-30 Ханми Фарм. Ко., Лтд. Glucagon derivatives with improved stability
AR105485A1 (en) 2015-06-30 2017-10-11 Hanmi Pharm Ind Co Ltd DERIVATIVE OF GLUCAGÓN AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME
CA3010265A1 (en) 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
CA3029518A1 (en) 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
EP3842449A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
JP2023541138A (en) * 2020-09-04 2023-09-28 ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス Derivatization of peptides and proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017039A1 (en) * 1993-01-19 1994-08-04 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5408037A (en) * 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
WO1997034631A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998028427A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
JPH07505915A (en) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド Dendritic macromolecules and their production method
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) * 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
WO1994017039A1 (en) * 1993-01-19 1994-08-04 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5665705A (en) * 1993-12-29 1997-09-09 The Rockefeller University Glucagon analogs with serine replacements
WO1997034631A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998028427A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Also Published As

Publication number Publication date
JP2003531632A (en) 2003-10-28
US20030032588A1 (en) 2003-02-13
EP1278772A2 (en) 2003-01-29
US6677136B2 (en) 2004-01-13
AU2001255798A1 (en) 2001-11-12
WO2001083527A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
WO2001083527A3 (en) Glucagon antagonists
WO2001081376A3 (en) Apo-ai/aii peptide derivatives
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
EP2014678A3 (en) KDR peptides and vaccines comprising the same
WO2005115306A3 (en) Keratin-binding polypeptides
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
JP2004534503A5 (en)
BR9914066A (en) Human complement c3-degrading polypeptide from streptococcus pneumoniae
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
WO2001083526A3 (en) Calcitonin-related molecules
WO2001004157A3 (en) NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
EP1500700A3 (en) Pectic acid lyase
WO2003070751A3 (en) Partial peptide mimetics and methods
WO2006029343A3 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
WO2002102847A1 (en) Novel ligand and dna thereof
WO2008084652A1 (en) Vascular endothelial cell-binding peptide
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
WO2007073845A8 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
WO2002083727A3 (en) Nucleic acid sequences of hyperplasies and tumors of the thyroid
WO2002059317A3 (en) Cub domain protein zcub3 and materials and methods for making it
Marchetto et al. Two short peptides including segments of subunit A of Escherichia coli DNA gyrase as potential probes to evaluate the antibacterial activity of quinolones
WO2009069546A1 (en) Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001929003

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001929003

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001929003

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)